04:18 PM EDT, 08/18/2025 (MT Newswires) -- Adaptive Biotechnologies ( ADPT ) shares fell 4.8% Monday after the company said its collaboration and license agreement with Genentech, a Roche subsidiary, will be terminated, effective Feb. 9.

Adaptive "will be released from exclusivity obligations with respect to cell therapies in oncology," according to a regulatory filing.

The company expects to recognize $33.7 million in H2 in noncash revenue from the remaining amortization of the cash consideration received under the Genentech agreement, which was signed in December 2018.